Abstract
Co-ordinate regulation of the gastric acid secretion and production of protective gastric mucosal phospholipids has been suggested. In the present study, the effects of vagotomy, and of equipotent antisecretory doses of ranitidine and omeprazole (with antisecretory effects similar to that of vagotomy) on the gastric mucosal phospholipid composition and content in rats were evaluated. Experimental groups 1, 2 and 3 were given ranitidine (400 µmol/kg), omeprazole (400 µmol/kg) or the vehicle only, by gavage every morning for 14 days, respectively. Groups 4 and 5 were subjected to surgical truncal vagotomy (TV) or surgical TV plus chemoneurolysis (CNL), respectively. Both procedures were performed with a pyloroplasty. Untreated (control) rats, rats in experimental groups 1, 2 and 3, and the rats that underwent surgery were sacrificed at the beginning of the study, 2 h after the last dose of ranitidine, omeprazole or vehicle, and 14 days after surgery, respectively. Biopsy specimens were taken at the lesser curvature of the antrum and corpus, and the lipid analyses were done. The individual phospholipids were identified by thin-layer chromatography. Phosphatidylcholine (PC), phosphatidylinositol (PI) and phosphatidylethanolamine (PE) were the main phospholipid classes. The level of PC was higher in the corpus than in the antrum. No differences between corporal and antral total phospholipid content was noticed. Ranitidine decreased the total phospholipid content in the corpus. Omeprazole, surgical TV and surgical TV+CNL decreased the levels of PC, PI and PE, as well as the total phospholipid content, both in the corpus and antrum. In conclusion, ranitidine and omeprazole, in doses that produced inhibition of acid secretion, and vagotomy decreased the content of gastric mucosal protective phospholipids. This may weaken the gastric defence and be of importance in the recurrence of gastric ulcers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Morgenroth K. The Surfactant System of the Lungs. Berlin: Walter de Gruyter; 1988.
Scheiman JM, Kraus ER, Bonnville LA, Weinhold PA, Boland CR. Synthesis and prostaglandin E2-induced secretion of surfactant phospholipid by isolated gastric mucous cells. Gastroenterology. 1991;100:1232–40.
Dobbie JW, Lloyd JK. Mesothelium secretes lamellar bodies in a similar manner to type II pneumocyte secretion of surfactant. Perit Dial Int. 1989;9:215–19.
Schmitz G, Müller G. Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids. J Lipid Res. 1991;32:1539–70.
Hills BA. The Biology of Surfactant. Cambridge: Cambridge University Press; 1988.
Hills BA. The role of lung surfactant. Br J Anaesth. 1990;65:13–29.
Hills BA. A physical identity for the gastric mucosal barrier. Med J Aust. 1990;153:76–81.
Hills BA, Butler BD, Barrow RE. Boundary lubrication impaired by pleural surfactants and their identification. J Appl Physiol. 1982;53:463–9.
Hills BA. Role of surfactant in the Eustachian tube. In: Ekelund L, Jonson B, Malm L, eds. Surfactant and the Respiratory Tract. Amsterdam: Elsevier Science Publishers (Biomedical Division); 1989:343–51.
Hills BA. A physical identity for the blood-brain barrier. Proc R Soc NSW. 1989;122:19–26.
Hills BA. Oligolamellar lubrication of joints by surface active phospholipid. J Rheumatol. 1989;16:82–91.
Ingstrup MH, Svane-Knudsen V, Brofeldt S, Larsen HF, Klintgaard N. Phospholipids in nasal secretion. In: Ekelund L, Jonson B, Malm L, eds. Surfactant and the Respiratory Tract. Amsterdam: Elsevier Science Publishers (Biomedical Division); 1989:311–16.
Butler BD, Lichtenberger LM, Hills BA. Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol. 1983;244:G645–51.
Arvidson G. Lipid composition of surfactant. In: Ekelund L, Jonson B, Malm L, eds. Surfactant and the Respiratory Tract. Amsterdam: Elsevier Science Publishers (Biomedical Division); 1989:29–31.
van Golde LMG, van Iwaarden JF, Batenburg JJ, Verhoef J. Metabolic aspects of pulmonary surfactant: synthesis by alveolar type II cells and possible interactions with alveolar macrophages. In: Ekelund L, Jonson B, Malm L, eds. Surfactant and the Respiratory Tract. Amsterdam: Elsevier Science Publishers (Biomedical Division); 1989:3–13.
Wassef MK, Lin YN, Horowitz MI. Phospholipid-deacylating enzymes of rat stomach mucosa. Biochem Biophys Acta. 1978;528:318–30.
Wassef MK, Lin YN, Horowitz MI. Molecular species of phosphatidylcholine from rat gastric mucosa. Biochem Biophys Acta. 1979;573:222–6.
Goddard PJ, Kao YCJ, Lichtenberger LM. Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel. Gastroenterology. 1990;98:361–70.
Kao YCJ, Goddard PJ, Lichtenberger LM. Morphological effects of aspirin and prostaglandin on the canine gastric mucosal surface. Analysis with a phospholipid-selective cytochemical strain. Gastroenterology. 1990;98:592–606.
Scheiman JM, Kraus ER, Boland CR. Regulation of canine gastric mucin synthesis and phospholipid secretion by acid secretagogues. Gastroenterology. 1992;103:1842–50.
Sengupta S, Piotrowski E, Slomiany A, Slomiany BL. Adrenergic and cholinergie regulation of gastric mucus phospholipid secretion. Scand J Gastroenterol. 1992;27:29–32.
Freston JW. Overview of medical therapy of peptic ulcer disease. Gastroenterol Clin N Am. 1990;19:121–40.
Salim AS. Surgery or chemoneurolysis for complete vagal denervation of rat stomach. Dig Dis Sci. 1991;36:1074–8.
Feldman M, Burton ME. Histamine H2-receptor antagonists. Standard therapy for acid—peptic diseases. N Engl J Med. 1990;323:1672–80.
Maton PN. Omeprazole. N Engl J Med. 1991;324:965–75.
Klaus M, Reiss OK, Tooley WH, Piel C, Clements JA. Alveolar epithelial cell mitochondria as source of the surface-active lung lining. Science. 1962;137:750–1.
Kunc L, Kuncova M, Holusa R, Solda F. Physical properties and biochemistry of lung surfactant following vagotomy. Respiration. 1978;35:192–7.
Piotrowski J, Yamaki K, Morita M, Slomiany A, Slomiany BL. Ebrotidine -a new H2-receptor antagonist with mucosal strengthening activity. Biochem Int. 1992;26:659–67.
Gill M, Sanyal SN, Sareen ML. Effect of histamine H2-receptor antagonist, ranitidine on renal brush border and basolateral membranes. Res Exp Med Berl. 1990;190:345–56.
Matsumoto A, Asada S, Okumura Y, Takiuchi H, Hirata I, Ohshiba S. Effects of anti-acid secretory agents on various types of gastric mucus. J Clin Gastroenterol. 1992;14(Suppl 1):S94–7.
Helander HF, Mattsson H, Elm G, Ottosson S, Structure and function of rat parietal cells during treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine. Scand J Gastroenterol. 1990;25:799–809.
Taylor TV, Holt S, Andrews PLR, Heading RC. Vagotomy by chemoneurolysis: an experimental study in the rat. Gut. 1983;24:158–60.
Salim AS. The mechanism of vagotomy-induced acute gastric mucosal injury in the rat. Am J Med Sci. 1989;297:343–7.
Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466–72.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Dunjić, B.S., Axelson, J., Dunjić, M.S., Hashmonai, M., Bengmark, S. (1997). Effects of Ranitidine, Omeprazole and Vagotomy on Rat Gastric Mucosal Phospholipids. In: Mózsik, G., Nagy, L., Pár, A., Rainsford, K.D. (eds) Cell Injury and Protection in the Gastrointestinal Tract. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5392-8_14
Download citation
DOI: https://doi.org/10.1007/978-94-011-5392-8_14
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6268-8
Online ISBN: 978-94-011-5392-8
eBook Packages: Springer Book Archive